Interviews

Eric Peacock, CEO of MyHealthTeams, discusses effective treatment of patients with chronic conditions.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.

Rinku A. Patel, PharmD, RPh, discusses how to improve communication among patients, physicians, pharmacists, and payers.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses how specialty pharmacies can best position themselves to access limited distribution drugs.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses how specialty pharmacies can help patients gain access to costly specialty drug regimens.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses how communication can be improved among specialty pharmacies, manufacturers, and pharmacy benefit managers.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how pharmacies can help patients manage high drug costs.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.

Mark A. Vineis, vice president of Specialty Pharmacy at Cardinal Health, discusses how specialty pharmacies can help achieve the goals of accountable care organizations.

Deborah Michaelson, MS, RPh, vice president of Operations at Ardon Health, discusses how pharmacies can help patients overcome the cost of high co-pays to maintain specialty drug adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the impact of prior authorizations on specialty pharmacy.

Grant E. Knowles, PharmD, discusses how the projected growth in specialty drug spending may change the patient experience in the years ahead.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

Pharmacists need to remain aware of certain interactions that can occur with medications and nutraceuticals.

Patients can use guidance about what vitamin products to select for their use.

Eric Peacock, co-founder and CEO of MyHealthTeams, discusses the importance of specialty pharmacies collaborating with patients in their care.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how specialty pharmacy can help patients manage high out of pocket costs for specialty drugs.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses how biosimilars could impact specialty pharmacy into the immediate future.

Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses the potential impact of value-based care on specialty pharmacy.

Jonathan Van Lare, PharmD, director of Clincal Services at Pharmacy Advantage, discusses the elements of a successful specialty pharmacy therapy management program.

Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses whether increased competition for specialty drugs can lower costs.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses methods pharmacists can employ to maintain adherence.

Daniel P. Kus, BS Pharm, RPh, vice president, Pharmacy Advantage, discusses key quality measures that define successful specialty pharmacies.

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.